Sākums › Multiplā mieloma › Džordžija › Atlanta
Multiplā mieloma klīniskie pētījumi Atlanta, GA
Viens pētījums par Multiplā mieloma meklē dalībniekus vietā Atlanta vai tās tuvumā. Atveriet to, lai redzētu, kas var piedalīties un kā sazināties ar pētījuma komandu.
Oficiālais pētījuma teksts (angļu valodā)
Meklējat dalībniekus pētījumam? Izceliet to šīs lapas augšdaļā — $99 par 30 dienām →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Notiek dalībnieku piesaiste3. fāze
- Research Site, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Emory University Winship Cancer Center, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste3. fāze
- Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Notiek dalībnieku piesaiste1. fāze
- Research Site, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Winship Cancer Institute Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste3. fāze
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Emory University Winship Cancer Institute, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Notiek dalībnieku piesaiste3. fāze
- Emory University - Winship Cancer Institute, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Notiek dalībnieku piesaiste4. fāze
- Emory University, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Emory University Hospital, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Notiek dalībnieku piesaiste2/3. fāze
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Notiek dalībnieku piesaiste2. fāze
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Winship Cancer Institute of Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
Notiek dalībnieku piesaisteNovērojumu pētījums
- Emory University, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Notiek dalībnieku piesaiste3. fāze
- Winship Cancer Institute, Emory University, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Notiek dalībnieku piesaiste3. fāze
- Emory University Hospital Midtown, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Notiek dalībnieku piesaiste2. fāze
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Emory University Hospital, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Research Site, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Research Site, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- The Winship Cancer Institute of Emory University, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Notiek dalībnieku piesaiste1/2. fāze
- Research Site, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Notiek dalībnieku piesaiste3. fāze
- Research Site, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Notiek dalībnieku piesaiste1. fāze
- Winship Cancer Institute, Emory University, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Winship Cancer Institute, Emory University, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Notiek dalībnieku piesaiste4. fāze
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Notiek dalībnieku piesaiste1/2. fāze
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Northside Hospital, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Notiek dalībnieku piesaiste1. fāze
- Winship Cancer Institute of Emory University, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Notiek dalībnieku piesaiste1/2. fāze
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Notiek dalībnieku piesaiste
- Emory University Hospital/Winship Cancer Institute, Atlanta
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Notiek dalībnieku piesaiste3. fāze
- Emory University Hospital, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Emory Winchip Cancer Center, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Notiek dalībnieku piesaiste3. fāze
- GSK Investigational Site, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
Notiek dalībnieku piesaiste2. fāze
- Caitlin Guzowski, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Emory University Hospital, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Notiek dalībnieku piesaiste1. fāze
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Notiek dalībnieku piesaiste1/2. fāze
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Notiek dalībnieku piesaiste1. fāze
- Northside Hospital, Atlanta
Multiplā mieloma pētījumi citās pilsētās
- New York City, NY60 pētījumi
- Boston, MA42 pētījumi
- Houston, TX38 pētījumi
- Durham, NC37 pētījumi
- Nashville, TN32 pētījumi
- Denver, CO27 pētījumi
- Rochester, MN24 pētījumi
- St. Louis, MO24 pētījumi
- Columbus, OH24 pētījumi
- Baldwin Park, CA23 pētījumi
- Chicago, IL22 pētījumi
- Seattle, WA22 pētījumi
Citi pētījumi Atlanta
- Vēzis (visi veidi)49 pētījumi
- Mazšūnu plaušu vēzis47 pētījumi
- Krūts vēzis41 pētījums
- Priekšdziedzera vēzis33 pētījumi
- Akūta mieloīdā leikēmija30 pētījumi
- Olnīcu vēzis29 pētījumi
- Plaušu vēzis29 pētījumi
- Kolorektālais vēzis29 pētījumi
- Metastātisks vēzis28 pētījumi
- Sirds mazspēja25 pētījumi
- Smags depresijas traucējums25 pētījumi
- Galvas un kakla plakanšūnu karcinoma24 pētījumi
No ClinicalTrials.gov, dati iegūti 2026. gada 5. okt.. Katram pētījumam ir savi dalības nosacījumi; pētījuma komanda nosaka, kas var piedalīties.